J&J psoriasis drug gets expanded U.S. approval for teens

(Reuters) – Johnson & Johnson said on Friday it has received an expanded U.S. approval for its blockbuster psoriasis drug Stelara to treat adolescent patients aged 12 and over with moderate to severe cases of the unsightly skin condition.
Original Article